More Than 90% of Metro Areas Recorded Home Price Increases in First Quarter of 2024
May 08, 2024 07:00 ET
|
National Association of Realtors®
Washington, D.C., May 08, 2024 (GLOBE NEWSWIRE) -- Key Highlights Single-family existing-home sales prices rose in 93% of measured metro areas – 205 of 221 – in the first quarter, up from...
Benitec Biopharma to Participate in the Citizens JMP Life Science Conference
May 01, 2024 08:00 ET
|
Benitec Biopharma Inc.
HAYWARD, Calif., May 01, 2024 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (NASDAQ: BNTC) (“Benitec” or the “Company”), a clinical-stage, gene therapy-focused, biotechnology company developing novel...
Benitec Biopharma Reports Positive Interim Clinical Trial Data for First OPMD Subject Treated with BB-301 in Phase 1b/2a Study
April 18, 2024 07:30 ET
|
Benitec Biopharma Inc.
-First efficacy signals demonstrated for a gene therapy under development for Oculopharyngeal Muscular Dystrophy (OPMD) which affects ~15,000 patients worldwide- - BB-301 facilitated improvements...
Benitec Biopharma Announces Oversubscribed Private Placement Financing of $40.0 Million
April 18, 2024 07:00 ET
|
Benitec Biopharma Inc.
HAYWARD, Calif., April 18, 2024 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (NASDAQ: BNTC) (“Benitec” or the “Company”), a clinical-stage, gene therapy-focused, biotechnology company developing novel...
UPDATE: Predicine Introduces PredicineCARE™ NGS Kit for Tumor Profiling
April 11, 2024 23:07 ET
|
Predicine
Predicine’s Decentralized Lab Testing Solution Facilitates Clinical Trials, Companion Diagnostics (CDx) Development, and Patient Testing on a Global Scale.
Benitec Biopharma to Host Virtual R&D Day to Discuss BB-301 Clinical Program in Oculopharyngeal Muscular Dystrophy on April 18, 2024
April 09, 2024 08:00 ET
|
Benitec Biopharma Inc.
HAYWARD, Calif., April 09, 2024 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (NASDAQ: BNTC) (“Benitec” or “Company”), a clinical-stage, gene therapy-focused, biotechnology company developing novel...
Predicine Announces Collaboration with Apollomics to Develop PredicineCARE™ as a Companion Diagnostic Assay in Lung Cancer
April 05, 2024 16:21 ET
|
Predicine
Collaboration Utilizing PredicineCARE™ Blood cfDNA NGS Assay Marks Progress in Employing Comprehensive Genomic Profiling for Detection of Select Alteration
Predicine Introduces PredicineCARE™ NGS Kit for Global Clinical Trials, CDx Development and Patient Testing
April 05, 2024 16:10 ET
|
Predicine
Predicine’s Decentralized Lab Testing Solution Facilitates Clinical Trials, Companion Diagnostics (CDx) Development, and Patient Testing on a Global Scale.
Predicine to Present 15 Liquid Biopsy Studies at AACR 2024
April 05, 2024 02:08 ET
|
Predicine
HAYWARD, Calif., April 05, 2024 (GLOBE NEWSWIRE) -- Predicine, Inc. A leading precision oncology company, announced today that it will present data from 15 ctDNA studies at AACR 2024, spotlighting...
North America Courier Express and Parcel Market Poised for Growth, Aided by Technology Advancements in Automation
March 22, 2024 18:18 ET
|
Research and Markets
Dublin, March 22, 2024 (GLOBE NEWSWIRE) -- The "North America Courier Express and Parcel Market Size and Forecast, Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: By Business...